IBBQ - From Underperformance To Opportunity: Biotech's Case For 2025
2025-01-29 06:30:00 ET
Summary
- Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking innovations like mRNA cancer vaccines and CRISPR-based therapies.
- Structural shifts, including operational discipline and AI-powered drug discovery, signal resilience and a long-term growth narrative for biotech, even amidst macroeconomic and regulatory challenges.
- Historically low valuations, coupled with sector rotation dynamics and favorable policy initiatives, position biotech as a compelling opportunity for investors seeking growth in 2025.
By Christopher Gannatti, CFA ...
From Underperformance To Opportunity: Biotech's Case For 2025